142 related articles for article (PubMed ID: 35489202)
1. Cryo-EM structures of the β
Nureki I; Kobayashi K; Tanaka T; Demura K; Inoue A; Shihoya W; Nureki O
Biochem Biophys Res Commun; 2022 Jun; 611():158-164. PubMed ID: 35489202
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM structure of the β3-adrenergic receptor reveals the molecular basis of subtype selectivity.
Nagiri C; Kobayashi K; Tomita A; Kato M; Kobayashi K; Yamashita K; Nishizawa T; Inoue A; Shihoya W; Nureki O
Mol Cell; 2021 Aug; 81(15):3205-3215.e5. PubMed ID: 34314699
[TBL] [Abstract][Full Text] [Related]
3. Modeling and simulation studies of human β3 adrenergic receptor and its interactions with agonists.
Sahi S; Tewatia P; Malik BK
Curr Comput Aided Drug Des; 2012 Dec; 8(4):283-95. PubMed ID: 22242799
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
Ohlstein EH; von Keitz A; Michel MC
Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
[TBL] [Abstract][Full Text] [Related]
5. Human β3-Adrenoreceptor is Resistant to Agonist-Induced Desensitization in Renal Epithelial Cells.
Milano S; Gerbino A; Schena G; Carmosino M; Svelto M; Procino G
Cell Physiol Biochem; 2018; 48(2):847-862. PubMed ID: 30032151
[TBL] [Abstract][Full Text] [Related]
6. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.
Tyagi P; Thomas CA; Yoshimura N; Chancellor MB
Int Braz J Urol; 2009; 35(1):76-83. PubMed ID: 19254402
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
Michel MC; Gravas S
Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
[TBL] [Abstract][Full Text] [Related]
9. Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.
Ellsworth P; Fantasia J
Expert Opin Investig Drugs; 2015 Mar; 24(3):413-9. PubMed ID: 25557359
[TBL] [Abstract][Full Text] [Related]
10. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.
García-Álvarez A; Pereda D; García-Lunar I; Sanz-Rosa D; Fernández-Jiménez R; García-Prieto J; Nuño-Ayala M; Sierra F; Santiago E; Sandoval E; Campelos P; Agüero J; Pizarro G; Peinado VI; Fernández-Friera L; García-Ruiz JM; Barberá JA; Castellá M; Sabaté M; Fuster V; Ibañez B
Basic Res Cardiol; 2016 Jul; 111(4):49. PubMed ID: 27328822
[TBL] [Abstract][Full Text] [Related]
11. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
Hicks A; McCafferty GP; Riedel E; Aiyar N; Pullen M; Evans C; Luce TD; Coatney RW; Rivera GC; Westfall TD; Hieble JP
J Pharmacol Exp Ther; 2007 Oct; 323(1):202-9. PubMed ID: 17626794
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Rosa GM; Ferrero S; Nitti VW; Wagg A; Saleem T; Chapple CR
Eur Urol; 2016 Feb; 69(2):311-23. PubMed ID: 26422675
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes.
Bordicchia M; Pocognoli A; D'Anzeo M; Siquini W; Minardi D; Muzzonigro G; Dessì-Fulgheri P; Sarzani R
J Hypertens; 2014 Feb; 32(2):389-96. PubMed ID: 24256707
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.
Igawa Y; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):177-83. PubMed ID: 23263450
[TBL] [Abstract][Full Text] [Related]
15. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density.
Yamamoto S; Kusabuka H; Matsuzawa A; Maruyama I; Yamazaki T
PLoS One; 2023; 18(9):e0290685. PubMed ID: 37656760
[TBL] [Abstract][Full Text] [Related]
16. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
Arch JR
Naunyn Schmiedebergs Arch Pharmacol; 2008 Aug; 378(2):225-40. PubMed ID: 18612674
[TBL] [Abstract][Full Text] [Related]
17. β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project.
Michel MC; Korstanje C
Pharmacol Ther; 2016 Mar; 159():66-82. PubMed ID: 26808167
[TBL] [Abstract][Full Text] [Related]
18. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study.
Coelho A; Antunes-Lopes T; Gillespie J; Cruz F
Neurourol Urodyn; 2017 Nov; 36(8):1972-1980. PubMed ID: 28185314
[TBL] [Abstract][Full Text] [Related]
19. β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes.
García-Prieto J; García-Ruiz JM; Sanz-Rosa D; Pun A; García-Alvarez A; Davidson SM; Fernández-Friera L; Nuno-Ayala M; Fernández-Jiménez R; Bernal JA; Izquierdo-Garcia JL; Jimenez-Borreguero J; Pizarro G; Ruiz-Cabello J; Macaya C; Fuster V; Yellon DM; Ibanez B
Basic Res Cardiol; 2014 Jul; 109(4):422. PubMed ID: 24951958
[TBL] [Abstract][Full Text] [Related]
20. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor.
D' Agostino G; Maria Condino A; Calvi P
Eur J Pharmacol; 2015 Jul; 758():115-22. PubMed ID: 25861936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
